Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-14 |
2024-09 |
0 |
N/A |
N/A |
N/A |
2024-08-09 |
2024-06 |
0 |
-0.51 |
N/A |
N/A |
2024-05-15 |
2024-03 |
0 |
-0.7 |
N/A |
N/A |
2024-03-29 |
2023-12 |
0 |
-5.48 |
N/A |
N/A |
2023-11-09 |
2023-09 |
0 |
-0.85 |
N/A |
N/A |
2023-08-14 |
2023-06 |
0 |
-1.51 |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2023-08-07 |
DUNTON ALAN WILLIAM |
Director |
25.69K |
Stock Award(Grant) |
2021-01-13 |
HERNANDEZ JOSEPH |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2023-08-07 |
HUFFMAN JANET |
Chief Financial Officer |
15.00K |
Stock Award(Grant) |
2019-03-24 |
JOSLYN ALAN F |
Chief Executive Officer |
66.67K |
Purchase |
2018-09-17 |
KOSKI FAMILY L P |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-08-07 |
KOSKI ROBERT C |
Director |
44.06K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
22.15K |
73.27K |
0.87% |
2023-06-29 |
Renaissance Technologies, LLC |
12.72K |
42.08K |
0.50% |
2023-06-29 |
Geode Capital Management, LLC |
12.45K |
41.19K |
0.49% |
2023-06-29 |
FMR, LLC |
2.60K |
8.59K |
0.10% |
2023-06-29 |
Tower Research Capital LLC (TRC) |
1.97K |
6.50K |
0.08% |
2023-06-29 |
UBS Group AG |
400.00 |
1.32K |
0.02% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-05-30 |
Fidelity Extended Market Index Fund |
7.95K |
23.68K |
0.31% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
7.33K |
24.26K |
0.29% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
2.01K |
6.00K |
0.08% |
2023-07-30 |
Schwab Capital Trust-Total Stock Market Index Fund |
1.68K |
6.55K |
0.07% |
2023-05-30 |
Fidelity Total Market Index Fund |
1.39K |
4.14K |
0.05% |
2023-08-30 |
iShares Core S&P Total U.S. Stock Market ETF |
994.00 |
3.58K |
0.04% |
Split |
Date |
1 : 60 |
2023-01-23 |
1 : 10 |
2018-01-22 |
1 : 10 |
2018-01-19 |
0.05 : 1 |
2010-09-28 |